Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.

Abstract	Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2, which has posed a significant threat to global health. Although the infection is frequently asymptomatic or associated with mild symptoms, in a small proportion of patients it can produce an intense inflammatory and prothrombotic state that can lead to acute respiratory distress syndrome, multiple organ failure, and death. Angiotensin-converting enzyme 2, highly expressed in the respiratory system, has been identified as a functional receptor for severe acute respiratory syndrome coronavirus-2. Notably, angiotensin-converting enzyme 2 is also expressed in the cardiovascular system, and there are multiple cardiovascular implications of COVID-19. Cardiovascular risk factors and cardiovascular disease have been associated with severe manifestations and poor prognosis in patients with COVID-19. More important, patients with COVID-19 may have thrombotic and coagulation abnormalities, promoting a hypercoagulable state and resulting in an increased rate of thrombotic and thromboembolic events. This review will describe the pathophysiological characteristics of the cardiovascular involvement following infection by severe acute respiratory syndrome coronavirus-2, with a focus on thrombotic and thromboembolic manifestations and implications for antithrombotic management.
Authors	Luis Ortega-Paz, Davide Capodanno, Gilles Montalescot, Dominick J Angiolillo
Journal	Journal of the American Heart Association (J Am Heart Assoc) Vol. 10 Issue 3 Pg. e019650 (02 02 2021) ISSN: 2047-9980 [Electronic] England
PMID	33228447 (Publication Type: Journal Article, Review)
Chemical References	Anticoagulants Fibrinolytic Agents Platelet Aggregation Inhibitors
Topics	Anticoagulants (therapeutic use) COVID-19 (complications, epidemiology) Fibrinolytic Agents (therapeutic use) Humans Pandemics Platelet Aggregation Inhibitors (therapeutic use) Thromboembolism (etiology, prevention & control) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!